Royce & Associates LP Increases Stock Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Royce & Associates LP boosted its position in shares of LifeMD, Inc. (NASDAQ:LFMD) by 14.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 901,041 shares of the company’s stock after acquiring an additional 114,710 shares during the period. Royce & Associates LP’s holdings in LifeMD were worth $4,721,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of LFMD. Vanguard Group Inc. boosted its holdings in LifeMD by 12.5% in the 1st quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company’s stock valued at $11,875,000 after purchasing an additional 128,701 shares during the period. Acadian Asset Management LLC boosted its stake in LifeMD by 261.8% during the first quarter. Acadian Asset Management LLC now owns 116,655 shares of the company’s stock valued at $1,198,000 after buying an additional 84,413 shares during the period. Calamos Advisors LLC purchased a new position in LifeMD during the second quarter worth about $394,000. The Manufacturers Life Insurance Company bought a new position in LifeMD in the 2nd quarter worth about $93,000. Finally, Los Angeles Capital Management LLC increased its stake in LifeMD by 852.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock worth $637,000 after acquiring an additional 108,822 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on LFMD shares. B. Riley began coverage on LifeMD in a report on Friday, August 23rd. They set a “buy” rating and a $11.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of LifeMD in a report on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Stock Performance

NASDAQ:LFMD opened at $5.26 on Tuesday. The company has a market capitalization of $227.81 million, a price-to-earnings ratio of -8.22 and a beta of 1.23. The business has a 50 day moving average of $4.99 and a 200 day moving average of $6.29. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. LifeMD, Inc. has a 1-year low of $3.99 and a 1-year high of $12.88.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.